ARTICLE | Company News

GlaxoSmithKline neurology news

November 15, 2010 8:00 AM UTC

The U.S. Department of Justice charged a former attorney at GlaxoSmithKline with obstruction and making false statements related to a 2002 FDA investigation into off-label promotion of antidepressant Wellbutrin SR bupropion. The DoJ alleges that Lauren Stevens falsely denied that GSK had promoted the drug for off-label uses even though she knew the company had sponsored numerous programs where the drug was promoted for unapproved uses. ...